Clostridium difficile colitis: A clinical review
Section snippets
Epidemiology
The frequency of CDI infection increased from 4.5 CDI cases per 1000 discharges in 2001 to 8.2 in 2010 with a mortality rate of around 7%.2 A population-based study by Lessa et al. estimated almost a half million cases in the United States in 2011, with 83,000 recurrences and 29,300 deaths.3
Clostridium difficile infection is triggered by toxin production from the bacteria. Normal bacterial flora is disrupted, the colon is colonized with the Clostridium difficile bacteria, and toxins are
Diagnosis
Diagnosis of CDI requires the presence of diarrhea (at least 3 unformed stools in 24 h) or radiographic evidence of ileus or toxic megacolon, in addition to positive stool testing for Clostridium difficile toxin or colonoscopic or pathologic findings showing pseudomembranes.9
Pseudomembranes are pathognomonic of the disease, but are present in only about 50% of patients who are toxin-assay positive. As many as 70% of patients may present with rectal sparing, and 10% may have pseudomembranes
Clinical features
The signs and symptoms of CDI range from self-limited diarrhea to a combination of symptoms which may include fever, elevated white blood cell count, abdominal pain and/or distention, and tachycardia. With worsening disease, patients may progress to renal failure, shock, intensive care unit admission, and an acute surgical abdomen. Several grading scales have been published to enable the clinician to identify the appropriate therapy for a patient with active infection (See Table 1, Table 2).
Medical management
Treatment of Clostridium difficile infection involves discontinuation of the offending antibiotic, whenever possible. Antiperistaltic agents should be avoided, at least until antibiotic therapy is well underway. Resuscitation should be initiated for patients with more advanced disease.
Metronidazole is the drug of choice for mild infection (500 mg by mouth three times a day for 10–14 days), while vancomycin should be used for more severe episodes (125 mg by mouth four times daily for 10–14 days).
Fecal microbiota transplantation
A form of fecal microbiota transplantation (FMT) has been used in Chinese medicine for at least 1700 years for the treatment of various gastrointestinal ailments.25 More recently, Eiseman, in 1958, described the use of fecal enemas in the treatment of four patients with Clostridium difficile colitis.26 Since that time, there have been sporadic reports in the literature, with a marked increase in the number of publications in the last several years, as reported by the NIH clinical trials
Surgical treatment
When medical therapy fails to improve patient status, surgical consultation should be obtained. Unfortunately, in most cases, this is a time of crisis.
Abdominal colectomy is the treatment of choice for severely ill patients. Patients with megacolon, perforation or an acute abdomen should have an emergency colectomy. A review of the Nationwide Inpatient Sample from 2001 to 2010 by Halabi et al. found a colectomy rate of hospitalized patients of 0.7% with an overall mortality rate of 30.7% for
Clostridium difficile infection in inflammatory bowel disease
Clostridium difficile infections have a marked significance in the population with coincidental diagnosis of inflammatory bowel disease (IBD). Review of isolated case studies collected over several decades has concluded that CDI negatively impacts the natural course of IBD. This includes increased disease flares, increased morbidity, and increased length of hospitalization.61 Unfortunately, the nature of immunosuppressive therapy often makes the diagnosis of CDI difficult in this population, as
Conclusion
Clostridium difficile infection is a major cause of healthcare-related diarrhea leading to increased morbidity and mortality in surgical patients. Increases in failure rates and resistance to current treatments have been clinical and economical challenges in the healthcare setting. New developments in pharmacologic agents, surgical management and other strategies have been developed to improve management of CDI.
Medical management of CDI is dependent on the severity of the infection.
Funding
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
References (83)
- et al.
The rise in Clostridium difficile infection incidence among hospitalized adults in the United States: 2001-2010
Am J Infect Control
(2014) Overcoming barriers to effective recognition and diagnosis of Clostridium difficile infection
Clin Microbiol Infect
(2012)- et al.
Kuijper EJ on behalf of the committee. European Society of Clincal Microbiology and Infectious Diseases: update of the treatment guidance document for Clostridium difficile infection
Clin Microbiol Infect
(2014) - et al.
From stool transplants to next-generation microbiota therapeutics
Gastroenterology
(2014) - et al.
Fecal microbiota transplant for recurrent Clostridium difficile infection: mayo Clinic in Arizona experience
Mayo Clin Proc
(2013) - et al.
Success of self-administered home fecal transplantation for chronic Clostridium difficile infection
Clin Gastroenterol H
(2010) - et al.
Development of fecal microbiota transplantation suitable for mainstream medicine
Clin Gastroenterol H
(2015) - et al.
Review of the emerging treatment of Clostridium difficile infection with fecal microbiota transplantation and insights into future challenges
Clin Lab Med
(2014) - et al.
Fecal transplantation, through colonoscopy, is effective therapy for recurrent Clostridium difficile infection
Gastroenterology
(2012) - et al.
Clostridium difficile colitis in the United States: a decade of trends, outcomes, risk factors for colectomy, and mortality after colectomy
J Am Coll Surg
(2013)
Impact of Clostridium difficile on inflammatory bowel disease
Clin Gastroenterol Hepatol
Incidence of Clostridium difficile infection in inflammatory bowel disease
Clin Gastroenterol Hepatol
Clostridium difficile enteritis: a new role for an old foe
Surgeon
Clostridium difficile enteritis: an early postoperative complication in inflammatory bowel disease patients after colectomy
J Gastrointest Surg
Detecting and treating Clostridium difficile infections in patients with inflammatory bowel disease
Gastroenterol Clin N Am
Microbial composition analysis of Clostridium difficile infections in an ulcerative colitis patient treated with multiple fecal microbiota transplantations
J Crohns Colitis
Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia
N Engl J Med
Burden of Clostridium difficile infection in the United States
N Engl J Med
Clostridium difficile colitis
N Engl J Med
Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis
J Antimicrob Chemother
The epidemiology of community-acquired Clostridium difficile infection: a population based study
Am J Gastroenterol
Antimicrobial-resistant strains of Clostridium difficile from North America
Antimicrob Agents Ch
Current status of Clostridium difficile infection epidemiology
Clin Infect Dis
Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA)
Infect Cont Hosp Ep
Clostridium difficile colitis
Clin Colon Rect Surg
Impact of clinical symptoms on interpretation of diagnostic assays for Clostridium difficile infections
J Clin Microbiol
Comparison of three commercial methods for rapid detection of Clostridium difficile toxins A and B from fecal specimens
J Clin Microbiol
Laboratory diagnosis of Clostridium difficile infections: there is light at the end of the colon
Clin Infect Dis
A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity
Clin Infect Dis
Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections
Am J Gastroenterol
For the OPT-80-003 clinical support group. Fidaxomicin versus vancomycin for Clostridium difficile infection
N Engl J Med
Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin
Clin Infect Dis
Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children
Cochrane Database Syst Rev
Probiotics for the prevention of Clostridium difficile - associated diarrhea: a systematic review and meta-analysis
Ann Intern Med
Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis
JAMA
Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis
Surgery
Clostridium difficile infection: current and emerging therapeutics
Curr Treat Option Infect Dis
Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea
J Clin Gastroenterol
Dynamics of the fecal microbiome in patients with recurrent and nonrecurrent Clostridium difficile infection
Genome Med
Cited by (34)
To give or not to give antibiotics is not the only question
2021, The Lancet Infectious DiseasesComparing outcomes of nonoperative treatment for adhesive small bowel obstruction with and without antibiotics
2021, Journal of Infection and ChemotherapyUltrasensitive and fast detection of pathogens using Europium-containing polystyrene nanospheres in a homemade portable NMR diagnostic system
2020, Sensors and Actuators, B: ChemicalCitation Excerpt :On the other hand, the latter has been regarded as a major hospital-acquired infection since 2001. However, none of the current clinical diagnostic methods for C. difficile-related diseases can achieve rapid detection with sufficient sensitivity and selectivity [26]. Despite the development of polymerase chain reaction-based testing methods, the homemade portable NMR diagnostic system can offer a fast and sensitive analytical platform for HBsAg and C. difficile detection.
Molecular features of lipoprotein CD0873: A potential vaccine against the human pathogen Clostridioides difficile
2019, Journal of Biological ChemistryRisk factors and outcomes of Clostridium difficile infection in hospitalized patients
2019, Biomedical JournalCitation Excerpt :Therefore, it is reasonable to give oral vancomycin, which has been found to be superior for the treatment of patients with severe CDI [16], to patients with severe underlying diseases, which have been associated with higher mortality in our previous study and many others [21–26]. Many observational studies have shown that prior treatment with antimicrobials is the main risk factor for CDI [11–13,27,28]. CDI is known to be the cause of up to 25% of antibiotic-associated diarrheal cases [8].